Investment Analysts’ Weekly Ratings Changes for Solid Biosciences (SLDB)

Solid Biosciences (NASDAQ: SLDB) recently received a number of ratings updates from brokerages and research firms:

  • 5/31/2024 – Solid Biosciences is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $20.00 price target on the stock.
  • 5/31/2024 – Solid Biosciences had its price target lowered by analysts at JPMorgan Chase & Co. from $12.00 to $10.00. They now have a “neutral” rating on the stock.
  • 5/20/2024 – Solid Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
  • 5/16/2024 – Solid Biosciences had its price target lowered by analysts at Barclays PLC from $21.00 to $18.00. They now have an “overweight” rating on the stock.

Solid Biosciences Stock Down 0.1 %

Shares of SLDB stock opened at $8.25 on Tuesday. The stock has a market cap of $316.64 million, a P/E ratio of -2.09 and a beta of 1.87. Solid Biosciences Inc. has a one year low of $1.81 and a one year high of $15.05. The stock has a fifty day moving average price of $9.98 and a 200 day moving average price of $8.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.94 and a quick ratio of 14.94.

Solid Biosciences (NASDAQ:SLDBGet Free Report) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $0.01. Analysts predict that Solid Biosciences Inc. will post -2.55 earnings per share for the current year.

Institutional Trading of Solid Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SLDB. Vestal Point Capital LP acquired a new stake in shares of Solid Biosciences in the fourth quarter valued at $209,000. Vanguard Group Inc. increased its position in Solid Biosciences by 283.9% in the first quarter. Vanguard Group Inc. now owns 1,244,575 shares of the company’s stock worth $16,578,000 after purchasing an additional 920,404 shares during the period. Janus Henderson Group PLC acquired a new stake in Solid Biosciences in the first quarter worth about $23,935,000. Artal Group S.A. increased its position in Solid Biosciences by 175.0% in the first quarter. Artal Group S.A. now owns 2,500,000 shares of the company’s stock worth $33,300,000 after purchasing an additional 1,590,781 shares during the period. Finally, Bain Capital Life Sciences Investors LLC increased its position in Solid Biosciences by 28.9% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 4,034,582 shares of the company’s stock worth $53,741,000 after purchasing an additional 904,160 shares during the period. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

Recommended Stories

Receive News & Ratings for Solid Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.